We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Effectiveness Evaluation of Additional Risk Minimization Measures for Adolescent Use of Aripiprazole in the European Union: Results from a Post-Authorization Safety Study.
- Authors
Landsberg, Wally; Al-Dakkak, Imad; Coppin-Renz, Antonia; Geis, Uli; Peters-Strickland, Timothy; van Heumen, Emiel; Rahman, Mirza
- Abstract
<bold>Introduction: </bold>Two risk minimization (RM) tools-a healthcare professional frequently asked questions (HCP-FAQs) brochure and a patient/caregiver information brochure (PCIB)-were developed for HCPs and for adolescents (aged ≥ 13 years) receiving aripiprazole for bipolar I mania and their caregivers.<bold>Objectives: </bold>This study evaluated the effectiveness of these RM tools in improving the awareness and education of HCPs and patients/caregivers.<bold>Method: </bold>The RM tools were distributed to HCPs (identified in agreement with the marketing authorization holder [MAH] and local regulatory authorities), who in turn distributed the PCIBs to patients/caregivers. A web-based survey was then conducted targeting HCPs and patients/caregivers.<bold>Results: </bold>The response rate was low: 118 of 23,282 invited HCPs and 16 patients/caregivers completed the survey. Overall, 42% (49/118) of HCP respondents were aware of aripiprazole RM tools; of these, 59% (29/49) of HCPs read them at least once and 66% (19/29) of these used the RM tools while discussing the benefit-risk profile of aripiprazole with patients/caregivers. In total, 30 of the 118 HCPs (25%) were aware of the PCIB, and 26 distributed it to their patients/caregivers, whereas seven HCPs advised them to read the brochure. Overall, 15 of the 16 patients/caregivers were aware of the PCIB, and 13 read/referred to it. Of these, 12 found the PCIB useful, and five monitored their weight while receiving aripiprazole and reported potential risks immediately to their HCP.<bold>Conclusion: </bold>The response rate to the survey was low, and the tools displayed limited utility and effectiveness in improving awareness and education in a small number of responders. Therefore, the aripiprazole risk management plan was amended, and the tools were discontinued.
- Subjects
ARIPIPRAZOLE; BIPOLAR disorder; CAREGIVERS; PATIENTS; MEDICATION safety; DRUG efficacy
- Publication
Drug Safety, 2018, Vol 41, Issue 8, p797
- ISSN
0114-5916
- Publication type
journal article
- DOI
10.1007/s40264-018-0662-2